On March 23, 2022 Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, reported the presentation of preclinical data demonstrating that its lymph node-targeted CpG TLR9 agonist, Amphiphile-CpG (AMP-CpG), induces potent immune and anti-tumor responses, at the STING & TLR-Targeting Therapies Summit 2022 Digital Event, being held virtually from March 22-24, 2022 (Press release, Elicio Therapeutics, MAR 23, 2022, View Source [SID1234610716]). The electronic presentation is accessible here.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to see the preclinical responses observed across studies with our AMP platform. These responses reinforce previous findings and continue to demonstrate how targeted delivery of AMP-CpG to the lymph nodes promotes a potent cellular immune response to the respective disease-associated antigens – validating our lymph node-targeted approach to treating cancer and infectious diseases," said Peter DeMuth, Ph.D., Chief Scientific Officer at Elicio Therapeutics. "These preclinical datasets have also informed our AMP boosting approach to enhance established T cell receptor therapies (TCR-Ts)."
The AMP platform is designed to deliver therapeutic payloads directly to the lymph nodes, the "schoolhouse" of the immune system, activating a potent, functional and durable immune response. Elicio’s AMP platform with the CpG adjuvant has been shown to enhance the accumulation of AMP-CpG bound payloads in the lymph nodes, thus educating the body’s immune cells and resulting in a more potent immune response. This has enabled Elicio to unlock the untapped potential of lymph node-targeting for the treatment of several indications. In SARS-CoV-2, for example, vaccination with AMP-CpG demonstrated potent and durable T cell responses across several variants of concern. When combined with TCR-Ts, AMP-CpG enhances TCR-T cell persistence and anti-tumor function. Elicio has also demonstrated potent responses with its AMP-CpG adjuvant across a range of other antigens including those from Epstein-Barr virus, human papillomavirus and influenza.
Presentation Details
Title: Lymph-Node Targeted TLR9 Agonists Enable Potent Cellular Immune Responses Against Cancer & Infectious Disease
Highlights from the Presentation
AMP-CpG efficiently targets the lymph nodes to promote potent and comprehensive innate immune activation resulting in enhanced T and B cell responses with improved functionality and persistence
Application of AMP-CpG enables potent anti-tumor responses in multiple settings of therapy including therapeutic vaccination and TCR-T cell therapy
Application of AMP-CpG enables potent and balanced immunity, including CD8 and CD4 T cells as well as neutralizing cross-reactive antibodies, against viral pathogens
About the Amphiphile Platform
Our proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the "brain center" of the immune system – the lymph nodes. We believe this site-specific delivery of disease-specific antigens, adjuvants, and other immunomodulators may efficiently educate, activate, and amplify critical immune cells, potentially resulting in induction and persistence of potent adaptive immunity required to treat many diseases. In preclinical models, we have observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability. We believe our AMP lymph node-targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes.
Our AMP platform, originally developed at the Massachusetts Institute of Technology, or MIT, has broad potential across cancers, infectious diseases and other disease indications to advance a number of development initiatives through internal activities, in-licensing arrangements or development collaborations and partnerships.
The Amphiphile platform is thought to deliver immunotherapeutics directly to the lymph nodes by latching on to the protein albumin, found in the bloodstream, as it travels to lymphatic tissue. In preclinical models, we have observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability.